Gastroenterology
Volume 125, Issue 2 , Pages 413-420 , August 2003

Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine

  • Tor C Savidge

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Tor C. Savidge, Ph.D., Developmental Gastroenterology Laboratory, Combined Program in Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital and Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA; fax: (617) 726-4172
    • Laboratory of Developmental Gastroenterology, Combined Department of Pediatric Gastroenterology & Nutrition, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
    • ,
  • Wei-hua Pan

      Affiliations

    • Laboratory of Developmental Gastroenterology, Combined Department of Pediatric Gastroenterology & Nutrition, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
    • ,
  • Paul Newman

      Affiliations

    • Laboratory of Developmental Gastroenterology, Combined Department of Pediatric Gastroenterology & Nutrition, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
    • ,
  • Michael O’Brien

      Affiliations

    • Department of Anatomic Pathology, Boston University School of Medicine, Boston, Massachusetts, USA
    • ,
  • Pauline M Anton

      Affiliations

    • Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    • ,
  • Charalabos Pothoulakis

      Affiliations

    • Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Received 31 July 2002 ,Accepted 8 May 2003.

References 

  1. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–210
  2. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2000;34:346–353
  3. Hecht G, Pothoulakis C, LaMont JT, Madara JL. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest. 1988;82:1516–1524
  4. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, Madara JL. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology. 1992;102:416–423
  5. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest. 1995;95:2004–2011
  6. Pothoulakis C, LaMont JT. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol. 2001;280:G178–G183
  7. Just I, Selzer J, von Eichel-Streiber C, Aktories K. The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile. J Clin Invest. 1995;95:1026–1031
  8. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, Aktories K. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature. 1995;375:500–503
  9. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985;47:349–352
  10. Mitchell TJ, Ketley JM, Haslam SC, Stephen J, Burdon DW, Candy DC, et al. Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut. 1986;27:78–85
  11. Triadafilopoulos G, Pothoulakis C, O’Brien M, LaMont JT. Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology. 1987;93:273–279
  12. Kim PH, Iaconis JP, Rolfe RD. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun. 1987;55:2984–2992
  13. Corthier G, Muller MC, Wilkins TD, Lyerly D, L’Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun. 1991;59:1192–1195
  14. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–397
  15. Kato H, Kato N, Watanabe K, Iwai N, Nakamura H, Yamamoto T, et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol. 1998;36:2178–2182
  16. Alfa MJA, Kabani D, Lyerly S, Moncrief LM, Neville A, Al-Barrak GK, et al. Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000;38:2706–2714
  17. Limaye AP, Turgeon DK, Cookson BT, Fritsche TR. Pseudomembranous colitis caused by a toxin A(−) B(+) strain of Clostridium difficile. J Clin Microbiol. 2000;38:1696–1697
  18. Pothoulakis C, LaMont JT, Eglow R, Gao N, Rubins JB, Theoharides TC, et al. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G protein. J Clin Invest. 1991;88:119–125
  19. Sullivan NM, Pellett S, Wilkins TD. Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun. 1982;35:1032–1040
  20. Castagliuolo I, Riegler M, Nikulasson S, Lu B, Gerard C, Gerard NP, et al. NK-1 receptor is required in Clostridium difficile-induced enteritis. J Clin Invest. 1998;101:1547–1550
  21. Savidge TC, Morey AL, Ferguson DJP, Fleming KA, Shmakov AN, Phillips AD. Human intestinal development in a severe-combined immunodeficient xenograft model. Differentiation. 1995;58:361–371
  22. Gibson UEM, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996;6:995–1001
  23. Fiorentini C, Fabbri A, Falzano L, Fattorossi A, Matarrese P, Rivabene R, et al. Clostridium difficile toxin B induces apoptosis in intestinal cultured cells. Infect Immun. 1998;66:2660–2665
  24. Pothoulakis C, Castagliuolo I, LaMont JT, Jaffer A, O’Keane JC, Snider RM, et al. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci U S A. 1994;91:947–951
  25. Mahida YR, Makh S, Hyde S, Gray T, Borriello SP. Effect of Clostridium difficile toxin A on human intestinal epithelial cells (induction of interleukin 8 production and apoptosis after cell detachment). Gut. 1996;38:337–347
  26. Branka JE, Vallette G, Jarry A, Bou-Hanna C, Lemarre P, Van PN, et al. Early functional effects of Clostridium difficile toxin A on human colonocytes. Gastroenterology. 1997;112:1887–1894
  27. Linevsky JK, Pothoulakis C, Keates S, Warny M, Keates AC, Lamont JT, et al. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am J Physiol. 1997;273:G1333–G1340
  28. Steiner TS, Flores CA, Pizarro TT, Guerrant RL. Fecal lactoferrin, interleukin-1 beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol. 1997;4:719–722
  29. Lowe DC, Savidge TC, Pickard D, Eckmann L, Kagnoff MF, Dougan G, et al. Characterization of candidate live oral Salmonella typhi vaccine strains harbouring defined mutations in aroA, aroC and htrA. Infect Immun. 1999;67:700–707
  30. Huang GTJ, Eckmann L, Savidge TC, Kagnoff MF. Infection of human intestinal epithelial cells with invasive bacteria upregulates apical intercellular adhesion molecule-1 (ICAM-1) expression and neutrophil adhesion. J Clin Invest. 1996;98:572–583
  31. Eckmann L, Stenson WF, Savidge TC, Lowe DC, Barrett KE, Fierer J, et al. Role of intestinal epithelial cells in the host secretory response to infection with invasive bacteria (bacterial entry induces epithelial prostaglandin H synthase-2 expression, and prostaglandin E2 and F2α production). J Clin Invest. 1997;100:296–309
  32. Seydel KD, Li E, Swanson PE, Stanley SL. Human intestinal epithelial cells produce proinflammatory cytokines in response to infection in a SCID mouse-human intestinal xenograft model of amebiasis. Infect Immun. 1997;65:1631–1639
  33. Seydel KD, Li E, Zhang Z, Stanley SL. Epithelial cell-initiated inflammation plays a crucial role in early tissue damage in amebic infection of human intestine. Gastroenterology. 1998;115:1446–1453
  34. Laurent F, Eckmann L, Savidge TC, Morgan GM, Theodos C, Naciri M, et al. Cryptosporidium parvum infection of human intestinal epithelial cells induces the polarised secretion of C-X-C chemokines. Infect Immun. 1997;65:5067–5073
  35. Sedel KB, Zhang T, Champion GA, Fichtenbaum C, Swanson PE, Tzipori S, et al. Cryptosporidium parvum infection of human intestinal xenografts in SCID mice induces production of human tumor necrosis factor alpha and interleukin-8. Infect Immun. 1998;66:2379–2382
  36. Lozniewski A, Muhale F, Hatier R, Marais A, Conroy MC, Edert D, et al. Human embryonic gastric xenografts in nude mice (a new model of Helicobacter pylori infection). Infect Immun. 1999;67:1798–1805
  37. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am. 2001;30:753–777
  38. Savidge T, Pan WH, Bush T, Deng WL. Human and transgenic grafting models to study enteric nervous system function and pathophysiology. (abstr) Gastroenterology. 2002;122:A25
  39. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262
  40. Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT, et al. Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralizing activity after passage through the human stomach and small intestine. Gut. 1999;44:212–217
  41. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother. 2001;45:2340–2347
  42. Heerze LD, Kelm MA, Talbot JA, Armstrong GD. Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis. J Infect Dis. 1994;169:1291–1296
  43. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun. 1999;67:527–538

☆ Supported by the Crohn’s and Colitis Foundation, and the National Institutes of Health (DK33506; DK40561).

PII: S0016-5085(03)00902-8

doi: 10.1016/S0016-5085(03)00902-8

Gastroenterology
Volume 125, Issue 2 , Pages 413-420 , August 2003

Article Tools

* Image Usage & Resolution